Keratolytic Conjugate Compositions for Multi-Etiology Dry Eye
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for dry eye disease (DED) are inadequate as they often fail to address the underlying etiologies of the condition, leading to variable outcomes for patients with different causes of the disease.
Innovation Solution
Development of compounds comprising immunomodulators and keratolytic agents, such as cilomilast, ruxolitinib, and tacrolimus, formulated in dermal and ophthalmic compositions to target multiple underlying causes of DED, modulating immune responses and reducing inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for dry eye disease are used, then treatment simplicity is maintained, but therapeutic effectiveness is insufficient because they fail to address multiple underlying etiologies
Solution Approach 1:
The patent combines multiple therapeutic agents with different mechanisms of action into a single pharmaceutical composition. The composition includes at least one agent from Category A (PDE4 inhibitors, JAK inhibitors, etc.), at least one from Category B (keratolytic agents), and at least one from Category C (anti-inflammatory agents), allowing simultaneous targeting of multiple disease etiologies including inflammation, immunomodulation, and keratinization disorders within one formulation
Solution Approach 2:
The pharmaceutical composition is designed to universally address multiple underlying causes of dry eye disease through its multi-component formulation. Each category of agents contributes different therapeutic functions: Category A agents modulate immune responses and inflammation, Category B agents address keratinization and epithelial health, and Category C agents provide additional anti-inflammatory coverage, creating a universal treatment that can effectiveness across diverse disease presentations
2Reliability
If existing treatments are used, then treatment cost is reduced, but disease response is poor for patients with different causes of disease
Solution Approach 1:
The patent merges multiple therapeutic agents into a single pharmaceutical composition that can be administered as one formulation. This combination approach allows the delivery of diverse therapeutic mechanisms (PDE4 inhibition, JAK inhibition, keratolytic action, anti-inflammatory effects) in a unified treatment regimen, improving disease response across patients with different etiologies while simplifying administration
3Adaptability or versatility
If existing treatments are used, then treatment simplicity is maintained, but ability to address multiple etiologies is insufficient
Solution Approach 1:
The pharmaceutical composition achieves universality by incorporating agents that target multiple disease mechanisms simultaneously. The composition can address inflammatory pathways, immunomodulatory disorders, and keratinization abnormalities within a single formulation, making it adaptable to patients with diverse underlying causes of dry eye disease including autoimmune conditions, meibomian gland dysfunction, and epithelial disorders
Solution Approach 2:
The patent employs a composite pharmaceutical formulation that integrates multiple classes of therapeutic agents with complementary mechanisms of action. This composite composition synergistically combines PDE4 inhibitors, JAK inhibitors, keratolytic agents, and anti-inflammatory agents to create a multi-faceted therapeutic approach that can simultaneously address inflammation, immune dysregulation, and epithelial health issues
Data Source
AI summary
Described herein are compositions and methods for the treatment or prevention of dermal or ocular surface disorders. Ocular surface disorders include ocular allergy, dry eye disease, ocular manifestation of graft versus host disease and other inflammatory and/or infectious diseases of the (e.g., anterior) surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate immunological, keratolytic, anti-inflammatory, and/or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.